 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
9 News |  |
- |||||| Newvast (atorvastatin strontium pentahydrate) / Hanmi
New trial: An Observational Study to Evaluate the Treatment of Newvast® Tab(Atorvastatin) in Korean Patients With Dyslipidemia (clinicaltrials.gov) - Sep 26, 2022
P=N/A, N=1716, Completed, Sponsor: Hanmi Pharmaceutical Company Limited
- | Newvast (atorvastatin strontium pentahydrate) / Hanmi
Journal: Tongxinluo Ameliorates Myocardial Ischemia-Reperfusion Injury Mainly via Activating Parkin-Mediated Mitophagy and Downregulating Ubiquitin-Proteasome System. (Pubmed Central) - Nov 7, 2021
TXL ameliorates MIRI via activating Parkin-mediated mitophagy in rats. The downregulation of the ubiquitin-proteasome system is also involved.
- || Rovelito (atorvastatin/irbesartan) / Hanmi, Sanofi
Trial completion date, Trial primary completion date, IO biomarker: Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension (clinicaltrials.gov) - Apr 2, 2018
P4, N=84, Recruiting, Sponsor: Sanofi
The downregulation of the ubiquitin-proteasome system is also involved. Trial completion date: May 2018 --> Jul 2019 | Trial primary completion date: May 2018 --> Jul 2019
- || Rovelito (atorvastatin/irbesartan) / Hanmi, Sanofi
Trial primary completion date, IO biomarker: Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension (clinicaltrials.gov) - May 5, 2017
P4, N=84, Recruiting, Sponsor: Sanofi
Trial completion date: May 2018 --> Jul 2019 | Trial primary completion date: May 2018 --> Jul 2019 Trial primary completion date: May 2017 --> May 2018
- |||| Rovelito (atorvastatin/irbesartan) / Hanmi, Sanofi
Enrollment open, IO biomarker: Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension (clinicaltrials.gov) - Oct 20, 2016
P4, N=84, Recruiting, Sponsor: Sanofi
Trial primary completion date: May 2017 --> May 2018 Not yet recruiting --> Recruiting
- ||||| Rovelito (atorvastatin/irbesartan) / Hanmi, Sanofi
New P4 trial, IO biomarker: Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension (clinicaltrials.gov) - Jul 23, 2016
P4, N=84, Not yet recruiting, Sponsor: Sanofi
- Newvast (atorvastatin strontium pentahydrate) / Hanmi
Enrollment open, Monotherapy: AVOCADO: Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid (clinicaltrials.gov) - Oct 30, 2013
P=N/A, N=194, Recruiting, Sponsor: Sang Hak Lee
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Newvast (atorvastatin strontium pentahydrate) / Hanmi, Rovelito (atorvastatin/irbesartan) / Hanmi, Sanofi
Enrollment change: Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia (clinicaltrials.gov) - Aug 11, 2013
P3, N=230, Completed, Sponsor: Hanmi Pharmaceutical Company Limited
Not yet recruiting --> Recruiting N=330 --> 230
- ||||||| Newvast (atorvastatin strontium pentahydrate) / Hanmi, Rovelito (atorvastatin/irbesartan) / Hanmi, Sanofi
Trial completion: Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia (clinicaltrials.gov) - Aug 7, 2013
P3, N=230, Completed, Sponsor: Hanmi Pharmaceutical Company Limited
N=330 --> 230 Active, not recruiting --> Completed
- ||| Newvast (atorvastatin strontium pentahydrate) / Hanmi, Rovelito (atorvastatin/irbesartan) / Hanmi, Sanofi
Trial completion: A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin (clinicaltrials.gov) - Mar 31, 2012
P1, N=52, Completed, Sponsor: Hanmi Pharmaceutical Company Limited
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| Newvast (atorvastatin strontium pentahydrate) / Hanmi, Rovelito (atorvastatin/irbesartan) / Hanmi, Sanofi
New P3 trial: Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia (clinicaltrials.gov) - Sep 27, 2011
P3, N=230, Completed, Sponsor: Hanmi Pharmaceutical Company Limited
- ||| Newvast (atorvastatin strontium pentahydrate) / Hanmi, Rovelito (atorvastatin/irbesartan) / Hanmi, Sanofi
New P1 trial: A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin (clinicaltrials.gov) - Sep 27, 2011
P1, N=52, Completed, Sponsor: Hanmi Pharmaceutical Company Limited